Murine hybridoma secreting monoclonal antibody anti-DcR1
Référence
86445-01
Inventeurs
Jean-Luc TAUPIN
Sophie DABURON
Statut commercial
Non-exclusive know-how licenses
Laboratoire
This invention has been developed at the “Composantes innées de la réponse immunitaire et différenciation” laboratory, a CNRS laboratory (UMR5164), in the Victor Segalen university, BORDEAUX 2, France.
Description
TECHNICAL DESCRIPTION
The present invention relates to a murine hybridoma secreting a monoclonall antibody targeting human DcR1. DcR1 is a receptor of the TRAIL receptors family, which are belong to the apoptosis-inducing members of the Tumor Necrosis Factor (TNF) receptor superfamily. DcR1 behaves as a decoy receptor inhibiting TRAIL-mediated cell death in several cellular systems.
The inventors also developed a control cell line which over expresses a c-myc-tagged chimeric membrane DcR1 protein and so can be used to test the specificity of the produced antibody.
INDUSTRIAL APPLICATIONS
This innovation could be used as a research reagent for the study of TRAIL-mediated apoptosis and its control by DcR1.
It can also be used for phenotyping normal and abnormal human cells and cell lines.
For further information, please contact us (Ref 86445-01)
Besoin de plus d'informations ?
Nous contacterTechnologies Liées
-
07.06.2016
Novel recombinant lectins and applications for the detection of pathological state markers
Santé / Thérapeutique, Diagnostic médical 06433-01
-
27.07.2015
A new class of compounds, inhibitors of advanced glycation end-products (AGE) formation, to prevent the deleterious effects of aging due to the formation of AGE
Santé / Thérapeutique, Autres technologies 01418-01
-
03.10.2013
Spheniscins: peptides with antimicrobial and food preserving properties
Santé / Thérapeutique 85437-01